Bioelectric Medicine Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2024 - 2030)

Bioelectric Medicine Market Trends & Drivers

Increasing Prevalence of Neurological and Cardiovascular Disorders

The rise in the prevalence of neurological disorders, such as epilepsy, learning disabilities, neuromuscular disorders, autism, attention-deficit/hyperactivity disorder (ADHD), brain tumors, and cerebral palsy, along with the growing healthcare expenditure and the advent of novel products in bioelectric medicine, will fuel the growth of the market in the coming years. For instance, according to the WHO, epilepsy is the most-common neurological disorder across the globe, as over 50 million individuals are suffering from it. Additionally, it is suspected that if the condition is diagnosed and treated with time, nearly 70% of the people could live a seizure-free life.

Moreover, the growing geriatric population is spurring the demand for bioelectric medicines, as this section of the population is more prone to chronic neurological and cardiovascular disorders. As per the U.S. Census Bureau, more than 54 million people aged 65 and older live in the U.S., accounting for roughly 16.5% of the country’s population. This number is expected to increase to 85.7 million by 2050 and make up 20% of the country’s population. To treat the elderly, the usage of electroceutical devices, including cardiac , implantable cardioverter defibrillators, deep-brain stimulators, and spinal cord stimulators, is rising.

Bioelectric Medicine Market Analysis

Implantable Cardioverter Defibrillators Are Most-Frequently Used

Implantable cardioverter defibrillators are the most frequently used of all the products, due to their wide range of applications. These medical devices make use of electrical stimulation and are extensively used in the treatment of arrhythmias, including atrial fibrillation, ventricular tachycardia, and atrial flutter. In addition to that, they are used in conjunction with other treatments, such as medications or surgery.

In this regard, the rising incidence of cardiac arrests and neurological conditions in the geriatric population is propelling the category. This part of society creates a continuously escalating demand for implantable devices, such as implantable cardioverter defibrillators cardiac pacemakers, deep-brain stimulators, and spinal cord stimulators.

Further, the rising pace of technological advancements and product approvals is driving the growth of this category. For instance, in July 2020, Abbott Laboratories received the FDA approval for its next-generation Gallant series of implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators. These devices have an improved design, battery longevity, and compatibility with magnetic resonance imaging. In addition to that, the devices support the Bluetooth technology and a new patient smartphone application for improved remote monitoring, thus enabling more-extensive patient and doctor engagement and streamlined communications.

Arrhythmia Category Dominates Market

The arrhythmia category held the largest market share, around 60%, in 2022, and it is projected to attain the highest growth rate during the forecast period. This is attributed to the increasing patient pool suffering from arrhythmias across the world who uses cardiac pacemakers and implantable cardioverter defibrillators. For instance, according to the National Heart, Lung, and Blood Institute, atrial fibrillation is the most-common arrhythmia, with more than 2.5 million people in the U.S. having this condition.

The category is also dominating the market due to the advancements in treatment procedures. Several market players are stressing over the augmentation of their business prospects by means of mergers, collaborations, and partnerships, which are enabling them to upgrade their research scope too. For instance, in December 2021, Boston Scientific Corporation initiated the clinical trial of its modular cardiac rhythm implant system, which includes a leadless pacemaker and an implantable cardioverter defibrillator. These two separate systems work simultaneously to keep the heart from beating too fast or too slow.

Furthermore, bioelectric medicines are successfully utilized for acute and chronic pain management. These conditions include complex regional pain syndrome, back pain, muscle pain, headaches and migraines, improper blood flow in the lower and upper limbs, temporomandibular joint (TMJ) syndrome, arthritis, scleroderma, and disorders of the nervous system, such as diabetic neuropathy. These medicines work by blocking pain signals to the brain and producing endorphins, thus helping in pain relief.

Increasing Prevalence of Neurological and Cardiovascular Disorders

The rise in the prevalence of neurological disorders, such as epilepsy, learning disabilities, neuromuscular disorders, autism, attention-deficit/hyperactivity disorder (ADHD), brain tumors, and cerebral palsy, along with the growing healthcare expenditure and the advent of novel products in bioelectric medicine, will fuel the growth of the market in the coming years. For instance, according to the WHO, epilepsy is the most-common neurological disorder across the globe, as over 50 million individuals are suffering from it. Additionally, it is suspected that if the condition is diagnosed and treated with time, nearly 70% of the people could live a seizure-free life.

Moreover, the growing geriatric population is spurring the demand for bioelectric medicines, as this section of the population is more prone to chronic neurological and cardiovascular disorders. As per the U.S. Census Bureau, more than 54 million people aged 65 and older live in the U.S., accounting for roughly 16.5% of the country’s population. This number is expected to increase to 85.7 million by 2050 and make up 20% of the country’s population. To treat the elderly, the usage of electroceutical devices, including cardiac pacemakers, implantable cardioverter defibrillators, deep-brain stimulators, and spinal cord stimulators, is rising.

Rising Adoption of Implantable Electroceutical Devices

The implantable electroceutical devices category held an around 80% share in 2022. This is primarily ascribed to the increasing prevalence of several neurological and cardiovascular illnesses. Along with that, the rising number of product approvals is driving the growth of this category.

For instance, in January 2021, Boston Scientific Corporation received the FDA approval for its fourth-generation Vercise Genus deep-brain stimulation system. The device is specifically designed to treat the symptoms of Parkinson’s disease by delivering targeted electrical stimulation through surgically implanted leads in the brain connected to an implantable pulse generator.

Wearable implantable electroceutical devices are mostly adopted for therapeutic electrostimulation due to their multiple advantages, including functionality, conformability, biocompatibility, and biodegradability. Nowadays, innovators generally put the emphasis on wearable implantable power sources, capable ES on targeted tissues and organs, and advanced conformable electrodes. There is a rising demand for implantable devices for various applications, such as muscle activation, heart stimulation, skin rejuvenation, and nerve modulation. Many of these devices are specially designed to activate the vagus nerve, which helps in improving the heart rhythm and breathing. Among the various kinds of implantable electroceutical devices, cardioverter defibrillators and pacemakers are extensively used for the treatment of heart disorders.

Hospitals To Witness Highest Growth Rate

The hospitals category is expected to grow at the highest rate, of around 7%, during the forecast period, based on end user. This will be due to the availability of cutting-edge devices for detecting and treating neurological and hearing disorders, along with highly skilled healthcare professionals, at these places. Several chronic diseases, such as epilepsy, Alzheimer’s, arrhythmias, chronic pain, and retinitis pigmentosa, involve the hospitalization of the patient. In 2022, according to the Alzheimer’s Association, roughly 6.5 million Americans aged 65 or above and about 73% aged 75 and above had Alzheimer's.

Moreover, the rising disposable income, along with the development of advanced medical devices for the treatment of various severe diseases, is expected to drive the application of electroceuticals in hospitals. Similarly, the demand for them is increasing owing to the rising number of patients and surging expenditure on healthcare research and development.

Regional Analysis

North America Makes Largest Contribution to Global Revenue Generation

North America dominated the market of bioelectric medicine, with a revenue share of around 40%, in 2022, owing to the high research and development investments, rising adoption of technologically advanced devices, presence of major players, and large number of hospitals in the region. Moreover, the rising healthcare spending is a major factor propelling the market in the region.

Furthermore, the various recent approvals given by the FDA to bioelectrical devices across the region are accelerating the adoption of electroceuticals. For instance, in March 2021, Medtronic plc announced that the FDA has approved its Intellis Platform, which features Differential Target Multiplexed (DTM) programming. The device is designed to treat chronic intractable pain in the back and legs.

Moreover, for ophthalmic conditions, in September 2021, Nu Eyne manufactured a unique wearable eye therapy device, CELLENA, powered by STM32WB55 dual-core Bluetooth LE microcontroller. This device uses electric current and the light emitted by the eyes and related nerves to treat eye dryness and fatigue, as well as to support healthy retinal functions.

Additionally, the Asia-Pacific market is expected to witness the fastest growth over the next few years. This can be attributed to the increasing prevalence of various health disorders, such as epilepsy, Alzheimer's disease, cardiac arrhythmias, and spinal cord injuries, rising government spending on the healthcare infrastructure, wide availability of clinical laboratories, and easy access to novel diagnostic technologies in the region. In addition, the rapidly increasing health insurance coverage in regional countries is propelling the industry. The insurance usually includes full reimbursement for hearing aids, pacemakers, and stimulators, as recommended by doctors, which is fueling the use of bioelectric medicines in this region.

Market Breakdown

This report offers deep insights into the bioelectric medicine industry, with size estimation for 2019 to 2030, the major drivers, restraints, trends and opportunities, and competitor analysis.

Based on End User

• Hospitals
• Clinics
• Ambulatory Surgery Centers

Based on Application

• Arrhythmia
• Pain Management
• Parkinson's Disease
• Depression
• Ischemia
• Epilepsy

Based on Device Type

• Implantable
• Non-Invasive

Based on Product

• Implantable Cardioverter Defibrillators  
• Cardiac Pacemakers
• Spinal Cord Stimulators
• Cochlear Implants
• Deep-Brain Stimulators
• Transcutaneous Electrical Nerve Stimulators
• Vagus Nerve Stimulators
• Sacral Nerve Stimulators
• Retinal Implants

Geographical Analysis

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
• Asia-Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Mexico
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • U.A.E.

Top Bioelectric Medicine Companies